The BalanceD-HF study is a Phase III, international, multi-center, randomized, double-blind, parallel-group, double-dummy, active-controlled, event-driven trial. It aims to evaluate the effect of the combination of balcinrenone and dapagliflozin versus dapagliflozin alone on cardiovascular death and heart failure (HF) events in patients with chronic HF and impaired kidney function who have recently experienced an HF event. Patients will be randomly assigned to receive one of the following treatments: balcinrenone/dapagliflozin 15 mg/10 mg, balcinrenone/dapagliflozin 40 mg/10 mg, or dapagliflozin 10 mg, along with corresponding placebos. The study duration is estimated to be 22 months, and it will be conducted at around 700 sites globally.